Print

Key Patrys Limited (PATZF.PK) Patents Allowed for Multiple Products in U.S., Europe and Japan  
4/13/2011 9:37:39 AM

Melbourne, Australia; 13 April, 2011: Patrys Limited (ASX: PAB) (the “Company”), a biopharmaceutical company focused on the development of completely new treatments for cancer, is pleased to announce it has recently been allowed patents for anti-cancer products PAT-SC1, PAT-LM1 and PAT-CM1.

The patents were all allowed over the past 90 days, and cover the three largest markets for drug sales U.S., Europe and Japan.

A patent was allowed by the Japanese Patent Office that covers the disease target for PAT-SC1, a modified form of CD55, a protein expressed on the surface of cancer cells. The claims in this patent give Patrys the potential to block other companies from developing products directed at the same target.

PAT-SC1 is a very promising clinical product that has already been evaluated in a human clinical trial involving gastric cancer patients. The results of that study were encouraging, as patients treated with PAT-SC1 experienced a significant survival benefit compared to a historical control set of patients that received similar treatment but for the PAT-SC1 antibody.

The United States Patent Office has allowed a patent that covers our proprietary antibody PAT-LM1 and similarly structured products that bind to the same target as PAT-LM1. That target is a protein called “NONO” that is present on the surface of cancer cells but not healthy cells. Given the claims covered by this patent, Patrys has the potential to block similar antibodies that bind to the same target as PAT-LM1.

PAT-LM1 has shown strong promise across a number of cancer indications. Patrys has completed preclinical safety toxicology studies for PAT-LM1 and has significantly progressed the GMP manufacturing processes for this product.

Finally, the European Patent Office has granted a patent covering our proprietary PAT-CM1 antibody and any similar antibody that binds to the same target as PAT-CM1. The claims in this patent provide Patrys with the potential to block others from developing antibodies similar in structure and function to PAT-CM1.

PAT-CM1, a natural human antibody from the Company’s platform, has shown promise for the treatment of solid tumours and metastases across a number of indications including pancreatic, lung, breast and gastric cancers. PAT-CM1 is currently in late stage preclinical development, for which a robust manufacturing system has already been established that can support clinical development.

These recent patent allowances reflect a very successful broader effort to obtain intellectual property protection for the Company’s pipeline on a global basis. The success of this plan is evident as an additional seven patents have been allowed in the past 12 months in a broad range of global markets. Patrys’ recent patent activity is summarised below:

In addition to the above, Patrys will continue to pursue patent protection for additional aspects of the above mentioned and other lead products in all major geographical regions.

“We are very pleased to be strengthening our patent portfolio for a number of products and on a global basis,” said Patrys’ Director of Business Operations, Juliet Findlay. “The antibody therapy space is very lucrative and attracts a lot of industry activity from large companies. It is absolutely imperative for companies such as Patrys, which is developing completely new treatments for cancer, to be able to protect its technologies and products.”

Patrys’ CEO Dan Devine added: “Given the great deal of scrutiny and high standards for issuing patents now applied by patent offices in most markets, particularly in major markets like the U.S., Europe and Japan, Patrys’ success in obtaining patents on such a broad scale is an endorsement of the novelty of our products, and reinforces the long-term commercial value of Patrys’ pipeline”.

For further information, please contact:

Patrys Limited:

Daniel Devine

Chief Executive Officer

P: +61 3 9670 3273

info@patrys.com

Patrys IR:

Rebecca Wilson

Buchan Consulting

P: +61 (0)417 382 391

rwilson@bcg.com.au

Patrys Media:

Tom Donovan

Buchan Consulting

P: +61 3 9866 4722

tdonovan@bcg.com.au

About Patrys Limited:

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibodies as therapies for cancer and other major diseases. Patrys has a deep pipeline of anti-cancer natural human antibodies that enable both internal development and partnering opportunities. More information can be found at www.patrys.com.

About Obtaining Patent Protection in the United States, Japan and Europe: A granted patent is issued by the United States Patent Office and the Japanese Patent Office about four (4) to six (6) months after allowance. In Europe, there is a nine (9) month post grant opposition period. None of Patrys’ patents have been opposed to date.


//-->